Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

IMATINIB ALTAN 100 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/IMATINIB ALTAN 100 MG CAPSULAS DURAS EFG

Approved

STANDARD

IMATINIB ALTAN 100 MG CAPSULAS DURAS EFG

Altan Pharmaceuticals Sa🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Oct 1, 2020
Approval ID: 277ffbcf1780e05e
Company: Altan Pharmaceuticals Sa
Type: Standard

Approval Details

Approval Id: 277ffbcf1780e05e
Drug Cima Aemps Name: IMATINIB ALTAN 100 MG CAPSULAS DURAS EFG
Register Number: 84440
Holder Company Name: Altan Pharmaceuticals Sa
Marketing Company Name: Altan Pharma Limited
Authorization Date: 2020-10-01
Dosage Form: CÁPSULA DURA
Dose: 100 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: No
Company Name: Altan Pharmaceuticals Sa

Active Ingredients

IMATINIB MESILATO

119,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Oct 1, 2020

Approval ID

277ffbcf1780e05e

Type

Standard

Back to CIMA-AEMPS Approvals